Anlotinib Hydrochloride Capsules in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Open, Single Arm, Exploratory Clinical Trial.

The First Affiliated Hospital with Nanjing Medical University0 sites40 target enrollmentDecember 31, 2018

ConditionsCancer of Liver

InterventionsAnlotinib

DrugsAnlotinib

Overview

Phase: Not Applicable
Intervention: Anlotinib
Conditions: Cancer of Liver
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Enrollment: 40
Primary Endpoint: PFS
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

This is a prospective, one-arm, exploratory clinical study to observe and evaluate the efficacy and safety of Anlotinib hydrochloride capsules in patients with advanced liver cancer.

Registry

clinicaltrials.gov

Start Date

December 31, 2018

End Date

December 31, 2020

Last Updated

7 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age: 18 to 75 years old.
•At least one measurable lesion (the length of spiral CT scan (\> 10mm) meets the requirements of RESCIST 1.1) is found in patients with HCC confirmed by histopathology or cytology or who meet the clinical diagnostic criteria.
•Inability or unwillingness to undergo surgery and transcatheter hepatic artery interventional therapy; if interventional therapy, radiotherapy or surgery has been accepted, it must be more than 4 weeks, and adverse reactions or wounds have fully recovered.
•No treatment with sorafenib or other systemic treatment was received. Patients who have used interventional chemotherapeutic drugs during interventional therapy may be enrolled in the group.
•Child-Pugh liver function rating: grade A or B; BCLC stage B or C.
•ECOG PS：0-
•The life expectancy is more than 12 weeks.
•The main organs are functioning normally, which meets the following criteria:
•(1) Blood routine examination: A. HB \> 90 g/L; (No blood transfusion within 14 days) B. ANC is more than 1.5 x /L; C. PLT is more than 50 x /L; (2) Biochemical examination: A. ALT and AST \< 5_ULN; B. TBIL \< 1.5_ULN; C. Plasma Cr \< 1.5_ULN.
•Subjects volunteered to join the study, signed informed consent, good compliance, with follow-up.

Exclusion Criteria

•Hepatobiliary and mixed cell carcinomas and fiberboard cell carcinomas are known; other malignant tumors (except cured cutaneous basal cell carcinomas and cervical carcinoma in situ) have been reported in the past or at the same time.
•Pregnant or lactating women .
•Patients with hypertension who could not be well controlled by antihypertensive drugs (systolic blood pressure \> 150 mmHg, diastolic blood pressure \> 100 mmHg), patients with myocardial ischemia or myocardial infarction above grade II, arrhythmias with poor control (including QTC interval \> 450 ms) and cardiac insufficiency of grade III-IV according to NYHA standard.
•Inability to swallow, chronic diarrhea and intestinal obstruction significantly affect drug use and absorption.
•There are clear concerns about gastrointestinal bleeding (such as local active ulcer lesions, fecal occult blood +) or more), and there is a history of gastrointestinal bleeding within 6 months.
•Central nervous system metastasis has occurred.
•Coagulation dysfunction (PT \> 16 s, APTT \> 43 s, TT \> 21 s, Fbg \< 2 g/L), with bleeding tendency or undergoing thrombolysis or anticoagulation therapy.
•Have a history of mental illness or psychotropic drug abuse.
•Peritoneal effusion with clinical symptoms requires therapeutic abdominal puncture or drainage, or Child-Pugh score (\> 2).